Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The evolution of the psychedelic revolution

Neuropsychopharmacology volume 47, pages 413–414 (2022)Cite this article

Subjects

Atrophy of pyramidal neurons in the prefrontal cortex (PFC) is a hallmark of stress-related neuropsychiatric diseases such as depression, post-traumatic stress disorder (PTSD), and addiction. Given the critical role of the PFC in top-down control of mood, fear, and reward, strategies aiming to restore PFC structure and function have the potential to be disease-modifying and broadly efficacious. Psychoplastogens are a class of compounds that can rapidly rectify pathological changes in PFC circuitry after a single administration, with ketamine and serotonergic psychedelics being prime examples [1]. The rapid and sustained therapeutic effects of psychoplastogens clearly differentiate them from traditional antidepressants.

Your institute does not have access to this article

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170–82.

    CAS  Article  Google Scholar 

  2. Olson DE. The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects. ACS Pharmacol. Transl. Sci. 2020;4:563–7.

    Article  Google Scholar 

  3. Dunlap LE, Azinfar A, Ly C, Cameron LP, Viswanathan J, Tombari RJ, et al. Identification of psychoplastogenic N,N-dimethylaminoisotryptamine (isoDMT) analogues through structure–activity relationship studies. J. Med. Chem. 2020;63:1142–55.

    CAS  Article  Google Scholar 

  4. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analog with therapeutic potential. Nature 2021;589:474–9.

    CAS  Article  Google Scholar 

  5. Lu J, Tjia M, Mullen B, Cao B, Łukasiewicz K, et al. An analog of psychedelics restores functional neural circuits disrupted by unpredictable stress. Mol. Psychiatry. https://doi.org/10.1038/s41380-021-01159-1 (2021).

  6. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184:2779–2792. e18.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank all the members of the Olson Lab for helpful discussions.

Funding

This work was supported by funds from the National Institutes of Health (R01GM128997 to DEO, T32MH112507 to LPC) and Delix Therapeutics. David E Olson is a co-founder of Delix Therapeutics, Inc, serves as the chief innovation officer, is a member of the board of directors, and receives consulting fees. Delix Therapeutics has licensed technology from the University of California, Davis related to this manuscript. Lindsay P Cameron has nothing to disclose.

Author information

Authors and Affiliations

  1. Neuroscience Graduate Program, University of California, Davis, Davis, CA, USA

    Lindsay P. Cameron

  2. Department of Chemistry, University of California, Davis, Davis, CA, USA

    David E. Olson

  3. Department of Biochemistry & Molecular Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA

    David E. Olson

  4. Center for Neuroscience, University of California, Davis, Davis, CA, USA

    David E. Olson

Authors
  1. Lindsay P. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David E. Olson
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors both contributed to the writing and editing of this manuscript.

Corresponding author

Correspondence to David E. Olson.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cameron, L.P., Olson, D.E. The evolution of the psychedelic revolution. Neuropsychopharmacol. 47, 413–414 (2022). https://doi.org/10.1038/s41386-021-01150-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41386-021-01150-y

Search

Advanced search

Quick links